ClinicalTrials.gg
CompletedNCT02257983Updated Nov 18, 2020

Protective Effects of EPI-743 on Noise-Induced Hearing Loss

A Phase 2 interventional study of EPI-743 and Placebo in Noise-induced Hearing Loss, sponsored by Edison Pharmaceuticals Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-18.

Sponsored by Edison Pharmaceuticals Inc (part of PTC Therapeutics) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Hearing Loss, Noise-Induced with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Hearing Loss, Noise-Induced · United States.

Enrollment
13th of 22
77 · median 106
Started
2014
with 1 other
Phase 2
7 of 24
none open now
Registered
6th of 24
by date
Lead sponsor
1 of 24
Edison Pharmaceuticals Inc

Among the 24 studies in Hearing Loss, Noise-Induced with a site in United States, this one is the 13th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2014, is one of 7 in phase 2, and was the 6th registered.

Hearing Loss, Noise-Induced

46 studies on the registry are indexed under Hearing Loss, Noise-Induced; 10 are open to participants now.

Browse Hearing Loss, Noise-Induced studies →

Open to participants now

6 of the 24 studies in Hearing Loss, Noise-Induced with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Hearing Loss, Noise-Induced studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hearing Loss, Noise-Induced with a site in United States, or all of them as a file.
02

Study summary

If effective, administration of EPI-743 should have protective effects against temporary noise-induced hearing loss.

03

Conditions studied

  • Noise-induced Hearing Loss

Keywords

  • hearing
  • noise
  • oxidative stress
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults ages 18-30
  • Abstention from use of Idebenone, CoQ10, Vitamin E and foods or beverages at least 30 days prior to treatment initiation
  • Non-smokers
  • Abstention from alcohol from day 0 and throughout the duration of study
  • Normal audiology exam
  • Subject must be able to swallow size 0 capsules

Exclusion criteria

Exclusion Criteria:

  • Allergy to EPI-743 or sesame oil or nuts
  • Any medical disordere that would prevent subject participation
  • Any prescription meds other than for or seasonal allergies
  • Any significant patient medical history (cancer, cardiovascular, pulmonary, cognitive, ADHD, hx. of migraines, neurological, kidney)
  • Fat malabsorption syndromes
  • Anticoagulation thereapy within 30 days of enrollment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Active comparator
    EPI-743

    EPI-743 400 mg P.O. TID

    Drug: EPI-743

  • Placebo comparator
    Placebo

    Sesame Oil, NF in sealed gelatin capsules to match the test product

    Drug: Placebo

Interventions

  • EPI-743 (2 capsules 200 mg each) taken at a dose of 400 mg P.O. TID for 9 days with noise exposure for 4 hours on Day 8.

    Also known as: VincerinoneTM, EPI743

  • DrugPlacebo

    2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.

    Also known as: Matching placebo

06

What researchers measure

Primary outcomes

  1. Pure tone audiometry

    Time frame: 9 days

Secondary outcomes

  1. Time to recovery following acute noise exposure

    Time frame: 9 days

07

Study locations

1 site
  • University of Florida
    Gainesville, Florida 32610, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Nov 2015, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2014
First posted
Oct 7, 2014
StartActual
Oct 31, 2014
Primary completionActual
Nov 30, 2015
CompletionActual
Feb 29, 2016
Results delay requested
Aug 17, 2020
Last update
Nov 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02257983
Responsible party
Sponsor
First posted
Oct 7, 2014
Start date
Oct 31, 2014
Primary completion
Nov 30, 2015
Completion
Feb 29, 2016
Last update
Nov 18, 2020

Study contacts

Colleen Le Prell, Ph.D
principal investigator · University of Florida

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha-tocotrienol quinone

Start the discussion